X4P-001 + Nivolumab
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma
Trial Timeline
Dec 7, 2016 → Aug 8, 2018
NCT ID
NCT02923531About X4P-001 + Nivolumab
X4P-001 + Nivolumab is a phase 1/2 stage product being developed by X4 Pharmaceuticals for Clear Cell Renal Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02923531. Target conditions include Clear Cell Renal Cell Carcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02923531 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Clear Cell Renal Cell Carcinoma